Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids.

Cancer research - 14 Nov 2025

Gillette Amani, Udgata Shirsa, Schmitz Alexa E, Stoecker Jordan N, Kratz Jeremy D, Deming Dustin A, Skala Melissa C

Abstract excerpt

Patient-derived cancer organoids (PDCO) are a valuable model to recapitulate human disease in culture, with important implications for drug development. However, current methods for rapidly and reproducibly assessing PDCOs are limited. Label-free imaging methods are a promising tool to measure organoid-level heterogeneity and rapidly screen drug responses in PDCOs. This study aimed to assess and predict PDCO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Leucovorin

Share to Optical Imaging

Share to Organoids

Share to Oxaliplatin

Share to Oxidation-Reduction

Source

Open in PubMed Open full text

Identifiers

PMID: 40920506
DOI: 10.1158/0008-5472.CAN-24-4958
PMCID: PMC12478055

Genes

KRAS
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids.PMID 40920506Read ↗

Wide-field optical redox imaging with leading-edge detection for assessment of patient-derived cancer organoidsSemantic proximity Read ↗

An automated image analysis pipeline for wide-field optical redox imaging of patient-derived cancer organoidsSemantic proximity Read ↗

“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”Semantic proximity Read ↗

Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolutionSemantic proximity Read ↗

Optical Metabolic Imaging of Heterogeneous Drug Response in Pancreatic Cancer Patient OrganoidsSemantic proximity Read ↗

Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responsesSemantic proximity Read ↗

Using Genetically Encoded Fluorescent Biosensors to Interrogate Ovarian Cancer MetabolismSemantic proximity Read ↗

Quantitative Spatial Analysis of Metabolic Heterogeneity Across in vivo and in vitro Tumor ModelsSemantic proximity Read ↗

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient responseSemantic proximity Read ↗

Insights into metabolic heterogeneity of colorectal cancer gained from fluorescence lifetime imagingSemantic proximity Read ↗

Unveiling radiobiological traits and therapeutic responses of BRAFV600E-mutant colorectal cancer via patient-derived organoidsSemantic proximity Read ↗

Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response earlySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.